- Home
- HSBC vs AMGN Comparison
HSBC vs AMGN Comparison
Compare HSBC & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSBC | AMGN |
|---|---|---|
| Founded | 1865 | 1980 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.5B | 181.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HSBC | AMGN |
|---|---|---|
| Price | $74.89 | $326.63 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 14 |
| Target Price | N/A | ★ $315.31 |
| AVG Volume (30 Days) | 1.7M | ★ 2.8M |
| Earning Date | 10-28-2025 | 02-03-2026 |
| Dividend Yield | ★ 4.37% | 3.17% |
| EPS Growth | N/A | ★ 65.12 |
| EPS | 0.93 | ★ 12.93 |
| Revenue | ★ $57,976,000,000.00 | $35,971,000,000.00 |
| Revenue This Year | $12.50 | $10.85 |
| Revenue Next Year | $2.06 | $1.71 |
| P/E Ratio | $80.68 | ★ $24.57 |
| Revenue Growth | 0.01 | ★ 10.56 |
| 52 Week Low | $45.66 | $253.30 |
| 52 Week High | $75.44 | $346.38 |
Technical Indicators
Market Signals| Indicator | HSBC | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.35 | 51.54 |
| Support Level | $74.37 | $312.39 |
| Resistance Level | $75.92 | $320.19 |
| Average True Range (ATR) | 0.68 | 6.82 |
| MACD | 0.41 | -2.77 |
| Stochastic Oscillator | 83.05 | 43.26 |
Price Performance
Historical ComparisonAbout HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in more than 50 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.